Wendy Béguelin
0000-0002-4894-9229
Publication & Citation Trends
Publications
0 total
A phase 1b trial of the EZH2 inhibitor tazemetostat combined with CAR T cell therapy in B cell lymphomas
Cited by 0
Semantic Scholar
EZH2 oncogenic mutation disrupts germinal center B cell dynamics and promotes early lymphomagenic behaviors
Cited by 0
Semantic Scholar
Author Correction: ChromaFold predicts the 3D contact map from single-cell chromatin accessibility OA
Cited by 0
Semantic Scholar
Spen loss drives extra-follicular diffuse large B cell lymphoma with female-specific lethality and TLR pathway therapeutic vulnerabilities
Cited by 0
Semantic Scholar
Sasp-driven immune evasion defines a novel African ancestry-associated DLBCL subtype with distinctive molecular and immune vulnerabilities
Cited by 0
Semantic Scholar
Consensus recommendations from the 2024 International Follicular Lymphoma Scientific Workshop
Cited by 0
Semantic Scholar
Synergistic antitumor effect of combined EZH2 and DOT1L inhibition in B-cell lymphoma. OA
Cited by 12
Semantic Scholar
EZH1/EZH2 inhibition enhances adoptive T cell immunotherapy against multiple cancer models.
Cited by 39
Semantic Scholar
Research Topics
Epigenetics and DNA Methylation
(47)
Immune Cell Function and Interaction
(36)
CAR-T cell therapy research
(34)
Lymphoma Diagnosis and Treatment
(33)
Cytokine Signaling Pathways and Interactions
(18)
Affiliations
Universidad de La Frontera
Consejo Nacional de Investigaciones Científicas y Técnicas
Cornell University
Weill Cornell Medicine
Experimental Medicine and Biology Institute